Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 536
- Registration Number
- NCT03338010
- Locations
- 🇨🇳
Wuxi People's Hospital, Wuxi, Jiangsu, China
🇨🇳No.2 Hospital Affiliated to Jilin University, Changchun City, Jilin, China
🇨🇳Dalian Med. Univ. No 2 Affiliate Hospital, Dalian, Liao Ning, China
A Study to Compare 2 Formulations of LY900014 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY900014-U200Drug: LY900014-U100
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 49
- Registration Number
- NCT03334448
- Locations
- 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1645
- Registration Number
- NCT03334435
- Locations
- 🇦🇺
Fremantle Dermatology, Perth, Western Australia, Australia
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇭🇺SZTE AOK Borgyogyaszati es Allergologiai Klinika, Szeged, Csongrad, Hungary
A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 660
- Registration Number
- NCT03334396
- Locations
- 🇲🇽
Hospital Univ. Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico
🇲🇽RM Pharma Specialists S.A. de C.V., Distrito Federal, Mexico
🇨🇳National Cheng Kung University Hospital, Tainan City, Taiwan
Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 615
- Registration Number
- NCT03334422
- Locations
- 🇭🇺
Oroshaza Varosi Onkormanyzat Korhaza, Oroshaza, Hungary
🇯🇵Nomura Dermatology Clinic, Yokohama-shi, Kanagawa, Japan
🇯🇵Yamate Dermatological Clinic, Shinjuku, Tokyo, Japan
A Study of Multiple Doses of LY3305677 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: LY3305677Drug: Placebo
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 56
- Registration Number
- NCT03325387
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT03322631
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Shinjuku-Ku, Tokyo, Japan
A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT03315780
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 111
- Registration Number
- NCT03311724
- Locations
- 🇺🇸
Valley Research, Fresno, California, United States
🇺🇸National Research Institute, Los Angeles, California, United States
🇺🇸University Clinical Investigators, Inc., Tustin, California, United States
A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 40
- Registration Number
- NCT03310411
- Locations
- 🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States